ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Chronic Myelomonocytic Leukemia
Syndrome

Acute Myeloid Leukemia (AML) trials near Boston, MA, USA:

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid...

Enrolling
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Drug: CLN-049

Phase 1

Cullinan Therapeutics Inc.

Boston, Massachusetts, United States and 6 other locations

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (TUSCANY)

to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...

Enrolling
Relapsed Adult AML
Leukemia, Myeloid, Acute
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Boston, Massachusetts, United States and 33 other locations

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML hav...

Enrolling
Acute Myeloid Leukemia (AML)
FLT3-mutated Acute Myeloid Leukemia
Drug: Azacitidine
Drug: Venetoclax

Phase 1, Phase 2

Astellas
Astellas

Boston, Massachusetts, United States and 19 other locations

Revumenib in Combination With 7+3 + Midostaurin in AML

3) mutated Acute Myeloid Leukemia (AML).The names of the study drugs involved in this study are:* Revumenib (SNDX...

Enrolling
AML
AML, Adult
Drug: Daunorubicin
Drug: Cytarabine

Phase 1

Richard Stone, MD

Boston, Massachusetts, United States and 1 other location

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML...

Active, not recruiting
Untreated AML
AML Arising From Antecedent Hematologic Disorder (AHD)
Drug: cytarabine
Drug: daunorubicin

Phase 1

Servier
Servier

Boston, Massachusetts, United States and 16 other locations

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed th...

Enrolling
Leukemia, Myeloid, Acute
Drug: Cytarabine
Drug: Bleximenib

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Boston, Massachusetts, United States and 33 other locations

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relaps...

Enrolling
AML, Adult Recurrent
MDS
Drug: Azacitidine
Drug: Decitabine

Phase 1

PureTech Health

Boston, Massachusetts, United States and 10 other locations

Ivosidenib as Post-HSCT Maintenance for AML

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute...

Enrolling
Acute Myeloid Leukemia (AML)
Hematopoietic Stem Cell Transplant (HSCT)
Drug: Placebo
Drug: Ivosidenib

Phase 2

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 1 other location

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance ...

Enrolling
Acute Myeloid Leukaemia (AML)
Leukemia
Drug: Azacitidine (AZA)
Drug: Tagraxofusp

Phase 1, Phase 2

Jacqueline Garcia, MD

Boston, Massachusetts, United States and 1 other location

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS.The interventions involved in t...

Enrolling
Acute Myeloid Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm
Drug: SL-401
Drug: Azacitidine

Phase 1

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 2 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems